Peter Y. Kim

About Peter Y. Kim

Who is it?: Actor
Birth Day: April 01, 1958
Alma mater: Stanford University, Cornell University
Known for: Discovering how proteins cause cell membranes to fuse, and pioneering efforts to develop an HIV vaccine based on inhibiting membrane fusion.
Institutions: Merck & Co., Inc.
Website: Peter S. Kim Lab at Stanford

Peter Y. Kim Net Worth

Peter Y. Kim was born on April 01, 1958, is Actor. Peter attended NYU and holds an MFA from the Yale School of Drama. He made his Off-Broadway debut in Yoko Ono's rock opera, "New York Rock" and has appeared on Broadway, Off-Broadway and regionally. He made his feature film debut in "Hackers" opposite Angelina Jolie and has appeared in numerous TV shows, films and commercials. He is a founding member of Mr. Miyagi's Theatre Company and co-creator of their critically acclaimed Off-Broadway comedy, "Sides: The Fear is Real...". He is the Associate Producer of OBIE award winning NAATCO (National Asian American Theatre Company), teaches at Princeton University's Program in Theater and is the recipient of the Lilah Kan Red Socks Award.
Peter Y. Kim is a member of Actor

💰 Net worth: Under Review

Some Peter Y. Kim images



Kim is of Korean descent. Kim grew up in Ridgewood, New Jersey the son of a single mother, and his first job was in 1974 at a Roy Rogers restaurant, where he earned money to pay for college. Kim earned his A.B. in chemistry at Cornell University in 1979 and trained as a Ph.D. in Biochemistry at Stanford University under the guidance of Robert Baldwin. While at Stanford, he was also a Medical Scientist Training Program Fellow.


Kim joined Merck in 2001 as executive vice President, Research and Development. He was promoted to President in January 2003. In this role Kim oversaw all of Merck's drug and vaccine research and development activities.


During his tenure, Merck gained approval of more than 20 new medicines and vaccines. These include Januvia (the first DPP-4 inhibitor for type 2 diabetes), Gardasil (the first vaccine for prevention of cervical cancer), Isentress (the first HIV integrase inhibitor), Zostavax (the first vaccine for the prevention of shingles in adults), Rotateq (an oral vaccine for the prevention of rotavirus infection in infants), and Victrelis (the first hepatitis C protease inhibitor). In 2013, he retired from Merck and was succeeded by Roger Perlmutter